Lipigon Pharmaceuticals AB (publ) (STO:LPGO)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.0030
-0.0002 (-6.25%)
Apr 24, 2026, 5:04 PM CET
Market Cap1.82M -89.6%
Revenue (ttm)n/a
Net Income-32.44M
EPS-0.08
Shares Out605.93M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume12,174,634
Average Volume13,421,005
Open0.0032
Previous Close0.0032
Day's Range0.0028 - 0.0034
52-Week Range0.0028 - 0.1935
Beta0.38
RSI33.72
Earnings DateMay 22, 2026

About STO:LPGO

Lipigon Pharmaceuticals AB (publ), a clinical-stage pharmaceutical company, develops drugs for lipid related diseases in Sweden. Its product pipeline consists of Lipisense project, which is in phase II for the treatment of severe hypertriglyceridemia disease; Dyslipidemia project, which is in preclinical trial to treat cardiovascular disease and severe hypertriglyceridemia; and CAP project, which is in preclinical trial to treat and prevent lung injury associated with community-acquired pneumonia. The company has a license agreement with Leader... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 7
Stock Exchange Nasdaq Stockholm
Ticker Symbol LPGO
Full Company Profile

Financial Performance

Financial Statements